Neutraceuticals: Effective for Migraines?
Studies suggest that magnesium, riboflavin, butterbur, coenzyme Q10, and certain nutraceutical combinations may have efficacy in preventing migraine. This slideshow reviews the evidence.
Psychosis in Patients With Parkinson Disease Without Dementia
How common is psychosis in PD? Implications? Risk factors? Insights here, and measures that may help.
Update on Stroke Risks
Two new studies shed light on risk factors for stroke and MI, and a third suggests neurologic use s for Zolpidem that don’t involve treating insomnia.
Tingling, Numbness in Lower Limbs: A Case Study
What do these images suggest is the cause of bilateral lower limb symptoms of 4 months’ duration?
The Human Epilepsy Project
Dr. Loeb summarizes a global and one-of-a-kind approach of biomarker and drug discovery using systems biology of human brain tissues.
Odor Identification: Marker for Early Alzheimer Disease?
OI may serve for research purposes as a simple and inexpensive indicator of evolving AD pathology. Details here.
Parkinson Disease: Functional Assessment, Gene Disruptions, and More
New Parkinson disease studies offer insights into topics such as LRRK2 G2019S transgene activity, preclinical drug development, and neuroprotection in Parkinson disease.
Migraine Risk Influenced by Extremes of Weight
Too many—or too few—pounds—could be a factor in migraine pathogenesis. Details here.
FDA Drug and Biologic Approvals for Neurology: 2017 Midyear Review
Seven new drugs were approved for treatment of neurological disorders, including Parkinson disease, multiple sclerosis, and amyotrophic lateral sclerosis.
Psychosis in Parkinson Disease
A host of neuropsychiatric disorders are intrinsic to Parkinson disease or occur as a complication of the dopaminergic therapies. Here's what to look for.
By clicking Accept, you agree to become a member of the UBM Medica Community.